Clinical Trial

Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 28, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The aim of this study is to explore the efficacy and safety of a new combination regimen of GnP regimen, SBRT and the anti-PD-1/VEGF bis-antibody, Ivonescimab, in patients with recurrent metastatic advanced pancreatic cancer. The efficacy predictive biomarkers of this combination regimen will be further explored through information such as spatial analysis of the tumor immune microenvironment.
Trial Details
NCT Number NCT06991491
Lead Sponsor West China Hospital
Conditions Pancreatic Cancer
Enrollment 29 participants
Start Date 2025-06-01
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-05-28